购物车
您的购物车当前为空
AZD8931 diFuMaric acid 是一种可逆的 ATP 竞争性 EGFR、ErbB2 和 ErbB3 抑制剂(IC50 分别为 4 nM、3 nM 和 4 nM)。
别名 4-[[4-[(3-氯-2-氟苯基)氨基]-7-甲氧基-6-喹唑啉基]氧基]-N-甲基-1-哌啶乙酰胺二富马酸盐
AZD8931 diFuMaric acid 是一种可逆的 ATP 竞争性 EGFR、ErbB2 和 ErbB3 抑制剂(IC50 分别为 4 nM、3 nM 和 4 nM)。

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 546 | 现货 | |
| 5 mg | ¥ 1,220 | 现货 | |
| 10 mg | ¥ 1,810 | 现货 | |
| 25 mg | ¥ 2,890 | 现货 | |
| 50 mg | ¥ 3,910 | 现货 | |
| 100 mg | ¥ 5,250 | 现货 | |
| 200 mg | ¥ 6,900 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,720 | 现货 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
| 产品描述 | AZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC50 of 4 nM, 3 nM and 4 nM, respectively). |
| 靶点活性 | EGFR:4 nM , ErbB2:3 nM , ERB3:4 nM |
| 体内活性 | AZD8931 显著抑制了 IBC 细胞的生长并在体外诱导了人类 IBC 细胞的凋亡。AZD8931 单药疗法抑制了异种移植瘤的生长[1]。 |
| 动物实验 | Two IBC cell lines SUM149 and FC-IBC-02 。Cell growth and apoptotic cell death were examined in vitro.?For the in vivo tumor growth studies, IBC cells were orthotopically transplanted into the mammary fat pads of immunodeficient mice.?AZD8931 was given by daily oral gavage at doses of 25 mg/kg, 5 days/week for 4 weeks.?Paclitaxel was subcutaneously injected twice weekly[1]. |
| 别名 | 4-[[4-[(3-氯-2-氟苯基)氨基]-7-甲氧基-6-喹唑啉基]氧基]-N-甲基-1-哌啶乙酰胺二富马酸盐 |
| 分子量 | 706.1 |
| 分子式 | C31H33ClFN5O11 |
| CAS No. | 1196531-39-1 |
| Smiles | OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC |
| 密度 | no data available |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 | |||||||||||||||||||||||||
| 溶解度信息 | DMSO: 30 mg/mL (42.49 mM), Sonication is recommended. | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
DMSO
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。 | ||||||||||||||||||||||||||
对于不同动物的给药剂量换算,您也可以参考 更多